Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470574 · ClinicalTrials.gov registry record · NA
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT00470574: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00470574 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00470574, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells. PURPOSE: This clinical trial is studying the side effects and how well giving vaccine therapy together with QS21 works in treating patients with metastatic breast cancer.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL QS21
- OTHER immunoenzyme technique
- OTHER immunologic technique
- BIOLOGICAL sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-03-20 |
| Est. Completion | 2020-01-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00470574
The ClinicalTrials.gov registry entry for NCT00470574 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00470574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00470574 about?
NCT00470574 is a clinical study titled "Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer". RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells. PURPOSE: This clinical trial is studying the side effects and how well giving vaccine therapy toget...
What is the current status of trial NCT00470574?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2007-03-20. Estimated completion is 2020-01-24.
What interventions are being tested in trial NCT00470574?
The interventions under investigation include: laboratory biomarker analysis (OTHER), QS21 (BIOLOGICAL), immunoenzyme technique (OTHER), immunologic technique (OTHER), sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00470574?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.